BiotechTubeBiotechTube
Home/Nxera Pharma/Miles Congreve
MC

Miles Congreve

Chief Scientific Officer, Sosei Heptares

Nxera Pharma

Therapeutic Areas

NeuroscienceImmuno-oncologyGastrointestinal

Nxera Pharma Pipeline

DrugIndicationPhase
HTL0018318Neurological Disorders (e.g., Cognitive Impairment)Phase 1
HTL'149SchizophreniaPhase 1
HTL0014242Neurological DisordersPreclinical
HTL0039732UndisclosedPreclinical
GPR52 AgonistSchizophreniaPreclinical
GPR35 AgonistInflammatory Bowel Disease (IBD)Preclinical
EP4 AntagonistOncology ImmunotherapyPreclinical
FexuprazanErosive Esophagitis (GERD)Phase 3

Leadership Team at Nxera Pharma

CC
Chris Cargill
President, Chief Executive Officer, Representative Director
ST
Shinichi Tamura
Founder and Chairman of the Board
ML
Mickey Lee
Chief Financial Officer, Senior Vice President of Corporate Development
MB
Matt Barnes
President of Heptares Therapeutics, Head of UK R&D
MW
Malcolm Weir
Executive Vice President, Head of Research & Development Strategy
RY
Ryohei Yoshii
Executive Vice President, Head of Japan Operations
FM
Fiona Marshall
Chief Scientific Officer & Founder, Sosei Heptares
TT
Tim Tasker
Chief Medical Officer
HI
Hironoshin Ishii
Independent Director
HO
Hiroko Ohta
Independent Director
View full Nxera Pharma profile